Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.34 USD
+0.01 (0.75%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.33 -0.01 (-0.75%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 43 | 90 | 150 | 229 | 147 |
Receivables | 39 | 40 | 51 | 67 | 39 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 22 | 38 | 61 | 116 |
Other Current Assets | 20 | 33 | 33 | 15 | 7 |
Total Current Assets | 118 | 185 | 272 | 371 | 310 |
Net Property & Equipment | 4 | 5 | 7 | 9 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 95 | 131 | 163 | 199 | 346 |
Deposits & Other Assets | 12 | 5 | 50 | 38 | 76 |
Total Assets | 242 | 356 | 526 | 644 | 771 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 18 | 34 | 41 | 39 |
Current Portion Long-Term Debt | 18 | 32 | 98 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 68 | 76 | 104 | 131 | 129 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 4 | 21 | 15 | 40 |
Total Current Liabilities | 100 | 130 | 256 | 187 | 208 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 43 | 43 | 21 | 25 | 33 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 17 | 34 | 0 | 96 | 76 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 103 | 115 | 137 | 63 | 32 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 272 | 351 | 449 | 397 | 376 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,578 | 1,562 | 1,537 | 1,425 | 1,189 |
Retained Earnings | -1,609 | -1,557 | -1,460 | -1,178 | -794 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -31 | 5 | 76 | 248 | 395 |
Total Liabilities & Shareholder's Equity | 242 | 356 | 526 | 644 | 771 |
Total Common Equity | -31 | 5 | 76 | 248 | 395 |
Shares Outstanding | 188.30 | 183.90 | 174.90 | 144.50 | 118.90 |
Book Value Per Share | -0.16 | 0.03 | 0.44 | 1.71 | 3.32 |
Fiscal Year End for Akebia Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 43 | 47 | 54 | 57 |
Receivables | NA | 39 | 23 | 20 | 18 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 16 | 18 | 21 | 21 |
Other Current Assets | NA | 20 | 22 | 24 | 25 |
Total Current Assets | NA | 118 | 110 | 118 | 121 |
Net Property & Equipment | NA | 4 | 4 | 4 | 5 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 95 | 104 | 113 | 118 |
Deposits & Other Assets | NA | 12 | 4 | 3 | 5 |
Total Assets | NA | 242 | 235 | 254 | 277 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 15 | 9 | 12 | 13 |
Current Portion Long-Term Debt | NA | 18 | 8 | 24 | 24 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 68 | 63 | 56 | 46 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 100 | 80 | 92 | 83 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 43 | 43 | 43 | 43 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 17 | 35 | 18 | 26 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 107 | 115 | 111 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 272 | 274 | 281 | 291 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,578 | 1,570 | 1,568 | 1,565 |
Retained Earnings | NA | -1,609 | -1,610 | -1,595 | -1,579 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -31 | -39 | -27 | -14 |
Total Liabilities & Shareholder's Equity | NA | 242 | 235 | 254 | 277 |
Total Common Equity | 0 | -31 | -39 | -27 | -14 |
Shares Outstanding | 209.30 | 188.30 | 188.30 | 185.90 | 185.90 |
Book Value Per Share | 0.00 | -0.16 | -0.21 | -0.14 | -0.08 |